Sales Growth and Core Operating Margin
Alcon delivered sales of $2.5 billion with a sales growth of 3%. The company also achieved a core operating margin of 20.8% and core diluted earnings of $0.73 per share.
Successful Product Launches
The company launched Unity VCS and PanOptix Pro, marking significant advancements in ophthalmic surgery and intraocular lens technology. These products are expected to boost future growth.
Acquisition and Strategic Initiatives
Alcon acquired a majority position in Aurion Biotech, focusing on corneal transplantation, and entered into a definitive merger agreement to acquire LENSAR, enhancing their innovative equipment portfolio.
Strong Performance in Contact Lenses
The PRECISION1 family, TOTAL30 family, and DAILIES TOTAL1 for astigmatism grew double digits in the first quarter, demonstrating strong market acceptance and growth potential.
Vision Care Segment Growth
Vision care sales reached $1.1 billion, with contact lens sales growing by 4% to $688 million, driven by product innovation and price increases.